Relacorilant (NCT07259317)

Name: Relacorilant trial for Adenocarcinoma (NCT07259317)
Uploaded: 2026-10-31T06:52:54.080Z
Duration: 1 min 26 s
Description: Relacorilant trial for Adenocarcinoma (NCT07259317). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07259317.

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma: a one-minute explainerNCT072593171 min

Relacorilant trial for Adenocarcinoma (NCT07259317). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with recently diagnosed metastatic pancreatic ductal adenocarcinoma and no previous chemotherapy for metastatic disease. Known BRCA mutations and prior gemcitabine or nab-paclitaxel for pancreatic cancer exclude participation.

The idea: add oral relacorilant around gemcitabine and nab-paclitaxel infusions. Relacorilant blocks glucocorticoid-receptor signaling, which can support cancer-cell growth. Early groups test different doses and schedules; later enrollment uses a selected dose. Researchers assess safety and how long patients live without cancer progression. Doses and schedules vary.

This phase 2 study plans 80 patients. Corcept sponsors nineteen recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.